Procedures
OCA, tumor, Tumor
TUMOR, TUMOR
Enrolled patients received escalating doses of oral veliparib starting at a dose of 50 mg twice daily approximately 12 hours apart on days 1–4 and 8–11 of each 21-day cycle. The veliparib dose was to be evaluated in up to six different dose levels increasing at 50 mg twice daily per dose level, starting with dose level 1 of 50 mg twice daily veliparib and dose level 6 of 300 mg twice daily veliparib (Molecular analysis was performed by the Oncomine Comprehensive Assay (OCA, Version 1, 2 or 3; Thermo Fisher Scientific), which interrogates a panel of cancer-related genes (143, 144, and 161 genes in OCA V1, V2, and V3, respectively) with next-generation sequencing. When available, a patient-matched germline DNA sample was sequenced in parallel with tumor DNA. One patient had Foundation One done by commercially, while all other molecular studies were performed in the Yale New Haven Hospital Tumor Profiling Laboratory.